May 13th 2024
Boehringer Ingelheim expands access to adalimumab biosimilar adalimumab-adbm through agreement with Quallent Pharmaceuticals,
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
No Difference in Pediatric Growth Rates with Infliximab Biosimilar vs Reference Agent
July 21st 2023A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease.
Ambroxol Repurposing Improves Biochemical Markers in Gaucher Disease
June 28th 2023Significant improvements seen in hematologic parameters, visceral volumes, and plasma biomarkers in patients with Gaucher disease, suggesting its potential as an alternative therapy, particularly for those who cannot access enzyme replacement therapy.
Cost-Effectiveness and Patient Benefit Balance of Methotrexate, DMARD Combination Therapy
Combination methotrexate plus bDMARDs, bsDMARDs, and tsDMARDs provided .009 to .33 quality-adjusted life years gained with additional costs of $15,957 to $60,722 when compared with standard of care.
Biosimilars Month in Review: May 2023
The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals.
Adalimumab, Etanercept, Infliximab Biosimilars Show Clinically Equivalence to Biologics in RA
The biosimilars were equivalent with the biologic regarding both ACR20 response achievement and change of Health Assessment Questionnaire-Disability Index (HAQ-DI) scores at month 6.